Skip to main content
main-content
Erschienen in: Current Allergy and Asthma Reports 10/2022

11.06.2022 | Asthma (V Ortega, Section Editor)

Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction–Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA

verfasst von: Zeynep Ferhan Ozseker, Kurtulus Aksu, Levent Cem Mutlu, Pinar Mutlu, Can Ozturk, The Turkish Respiratory Society, Asthma, Allergic Respiratory Disease Scientific Committee

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This expert opinion, prepared by a panel of chest disease specialists, aims to review the current knowledge on practice patterns in real-life management of mild asthma and to address the relevant updates in asthma treatment by The Global Initiative for Asthma (GINA) to guide clinicians for the best clinical practice in applying these new treatment paradigms.

Recent Findings

On the basis of the emerging body of evidence suggesting the non-safety of short-acting β2-agonists (SABA)-only therapy and comparable efficacy of the as-needed inhaled corticosteroids (ICS)-formoterol combinations with maintenance ICS regimens, GINA recently released their updated Global Strategy for Asthma Management and Prevention Guide (2019). The new GINA 2019 recommendations no longer support the SABA-only therapy in mild asthma but instead includes new off-label recommendations such as symptom-driven (as-needed) low-dose ICS-formoterol and “low dose ICS taken whenever SABA is taken.” The GINA 2019 asthma treatment recommendations include a major shift from long-standing approach of clinical practice regarding the use of symptom-driven SABA treatment alone in the management of mild asthma.

Summary

This expert opinion supports the transition from a long-standing SABA-only approach to a risk reduction–based strategy, with the use of symptom-driven (as-needed) low-dose ICS/LABA in mild asthma patients, particularly in those with poor adherence to controller medications. The thoughtful and comprehensive approach of clinicians to these strategies is important, given that the exact far-reaching impact of this major change in management of mild asthma in the real-world settings will only be clarified over time.
Literatur
2.
Zurück zum Zitat Ishmael FT. The inflammatory response in the pathogenesis of asthma. J Am Osteopath Assoc. 2011;111(11 Suppl 7):S11–7. PubMed Ishmael FT. The inflammatory response in the pathogenesis of asthma. J Am Osteopath Assoc. 2011;111(11 Suppl 7):S11–7. PubMed
3.
Zurück zum Zitat •• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. https://​ginasthma.​org/​. Accessed 5 May 2021. The updated Global Strategy for Asthma Management and Prevention Guide was released by Global Initiative for Asthma (GINA) in 2019, based on the growing evidence on the non-safety of SABA-only therapy and superiority of the as-needed ICS-formoterol combinations over maintenance ICS regimens. •• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. https://​ginasthma.​org/​. Accessed 5 May 2021. The updated Global Strategy for Asthma Management and Prevention Guide was released by Global Initiative for Asthma (GINA) in 2019, based on the growing evidence on the non-safety of SABA-only therapy and superiority of the as-needed ICS-formoterol combinations over maintenance ICS regimens.
7.
Zurück zum Zitat •• Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK. It is time to change the way we manage mild asthma: an update in GINA 2019. Respir Res. 2019;20(1):183. https://​doi.​org/​10.​1186/​s12931-019-1159-y. The new GINA 2019 recommendations for asthma treatment no longer support the symptom-driven SABA-only therapy in mild asthma, instead offer new off-label approaches for the two treatment steps (Steps 1 and 2), including symptom-driven (as-needed) low dose ICS-formoterol and “low dose ICS taken whenever SABA is taken”. •• Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK. It is time to change the way we manage mild asthma: an update in GINA 2019. Respir Res. 2019;20(1):183. https://​doi.​org/​10.​1186/​s12931-019-1159-y. The new GINA 2019 recommendations for asthma treatment no longer support the symptom-driven SABA-only therapy in mild asthma, instead offer new off-label approaches for the two treatment steps (Steps 1 and 2), including symptom-driven (as-needed) low dose ICS-formoterol and “low dose ICS taken whenever SABA is taken”.
59.
Zurück zum Zitat Davidsen JR. Drug utilization and asthma control among young Danish adults with asthma. Analyses of trends and determinants. Dan Med J. 2012;59(8):B4501. Davidsen JR. Drug utilization and asthma control among young Danish adults with asthma. Analyses of trends and determinants. Dan Med J. 2012;59(8):B4501.
69.
Zurück zum Zitat Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–28. https://​doi.​org/​10.​1016/​S0140-6736(19)31948-8. CrossRefPubMed Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–28. https://​doi.​org/​10.​1016/​S0140-6736(19)31948-8. CrossRefPubMed
Metadaten
Titel
Expert Opinion on Practice Patterns in Mild Asthma After the GINA 2019 Updates: A Major Shift in Treatment Paradigms from a Long-Standing SABA-Only Approach to a Risk Reduction–Based Strategy with the Use of Symptom-Driven (As-Needed) Low-Dose ICS/LABA
verfasst von
Zeynep Ferhan Ozseker
Kurtulus Aksu
Levent Cem Mutlu
Pinar Mutlu
Can Ozturk
The Turkish Respiratory Society, Asthma, Allergic Respiratory Disease Scientific Committee
Publikationsdatum
11.06.2022
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 10/2022
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-022-01038-x

Neu im Fachgebiet HNO

07.12.2022 | Praxis konkret

Haftungsrisiken in der Praxis reduzieren

Welche Versicherungen sich lohnen - und welche nicht

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.